The upstream kinase. Further file 10: Distances between the kinome profiling data of cells treated with MK-2206. Unsupervised hierarchical clustering depicting the distances between information obtained from kinome profiling of cells treated with different concentrations of MK-2206 and for diverse time intervals. 1_30: remedy of 30 min with 1 M of MK-2206, and so forth. Abbreviations ALL: Acute lymphoblastic leukemia; DE: Differentially expressed; FDR: False discovery price; adjP: FDR adjusted P-value; IC50: Half maximal inhibitory concentration; IPA: Ingenuity pathways evaluation; logFC: Log fold transform; MSC: Mesenchymal stem cell; Ser/Thr: Serine/threonine. Competing interests Riet Hilhorst and Monique Mommersteeg are PamGene International B.V. workers. The other authors declare that they have no conflict of interests. Authors’ contributions MLK performed all bioinformatics analyses and wrote the manuscript. RH and MM performed kinome profiling experiments. BEWMA and MLK performed inhibition studies. EPB and MS had been involved in collection of cell line data. MLK, AMC, PCWH, RH, and HB developed the study. All authors read and authorized the final version on the manuscript.Price of Indium trichloride,99.99% Acknowledgments The authors would prefer to thank N. Duinkerken for the NALM-6 cell line. This study was funded by EuroBoNeT (LSHC-CT-2006-018814), the Dutch Cancer Society (KWF, 2008?060), the Netherlands Organization for Wellness Analysis and Improvement (92003?99). Author facts 1 Department of Pathology, Leiden University Healthcare Center, Albinusdreef two, 2300RC Leiden, The Netherlands. 2Current affiliation: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA. 3Current affiliation: Division of Biostatistics, Harvard School of Public Well being, Boston, MA, USA. 4PamGene International BV, `s-Hertogenbosch, The Netherlands.3-Fluoro-5-nitrophenol Chemscene 5Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.PMID:23800738 6Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy. 7Institute of Pathology, Paderborn/H ter, Germany. Received: 24 April 2013 Accepted: 14 January 2014 Published: 21 January 2014 References 1. Raymond AK, Ayala AG, Knuutila S: Standard osteosarcoma. In Planet Health Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Edited by Fletcher CDM, Unni KK, Mertens F. Lyon: IARC Press; 2002:264?70.two.3.four.five.6. 7.eight. 9.ten.11. 12.13.14.15.16.17.18.19.20.Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P: Prognostic things for osteosarcoma with the extremity treated with neoadjuvant chemotherapy – 15-year practical experience in 789 patients treated at a single institution. Cancer 2006, 106:1154?161. Buddingh EP, Anninga JK, Versteegh MI, Taminiau AH, Egeler RM, van Rijswijk CS, Hogendoorn PCW, Lankester AC, Gelderblom H: Prognostic components in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer 2010, 54:216?21. Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C, Menendez LR: A meta-analysis of osteosarcoma outcomes within the modern day health-related era. Sarcoma 2012, 2012:704872. Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AHM, Hogendoorn PCW, Egeler RM: Chemotherapeutic adjuvant therapy for osteosarcoma: where do we stand? Eur J Cancer 2011, 47:2431?445. Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M: Emerging drugs for high-grade osteosarcoma. Specialist Opin Emerg Drugs 2010, 15:615?34. Cleton-Jansen AM, Buerger H, Hogendoom PCW:.